17 employees
NewLimit is creating epigenetic reprogramming medications to cure diseases with significant unmet medical needs.
2022
$40M
from 3 investors over 3 rounds
NewLimit raised $40M on May 16, 2023
Investors: Founders Fund, Dimension and Kleiner Perkins